9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition

Malignant Pleural Mesothelioma

Estimated Enrollment: 33

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: N16INM

Study First Received: October 24, 2016

Last Updated: February 7, 2017

Estimated Primary Completion Date: September 2018

Primary Outcome Measures:

Disease Controle Rate (DCR) at 12 weeks|Safety: the incidence of adverse events, serious adverse events, deaths and laboratory abnormalities.|Disease Controle Rate (DCR) at 6 months|Progression Free Survival (PFS)|Overall Survival (OS)|Overall Response Rate (ORR)

Sponsors and Collaborators:

The Netherlands Cancer Institute|Bristol-Myers Squibb

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT03048474

Was this article helpful?
Views: 51